Effect of injection sites of botulinum toxin for blepharospasm treatment: statistical analysis

References

• Berardelli A. Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain 1985;108:593–608.
   Google Scholar
• Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm mechanism, diagnosis and management. J Am Med Assoc 1982;248:3160–3164.
   Web of Science ®Google Scholar
• Elston JS. Botulinum toxin A in clinical medicine. J Physiol 1990; 84:285–289.
   Google Scholar
• Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324:1186-1194.
   Google Scholar
• Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin injection as a treatment for blepharospasm. Arch Ophthalmol I985;103:347-35o.
   Google Scholar
• Mauriello JA Jr, Coniaris H, Haupt EJ. Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmology 1987;94;976–979.
   Google Scholar
• Elston J. Botulinum toxin therapy for involuntary facial movements. Eye 1988;2:12–15.
   Google Scholar
• Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatr 1988;51:767–772.
   PubMed Web of Science ®Google Scholar
• Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529–1534.
   PubMed Web of Science ®Google Scholar
• Mauriello JA Jr, Dhillon S, Leone T, Pakeman B, Mostafavi R, Yepez MC. Treatment selections of 239 patients with blepharospasm and Meige syndrome over I I years. Br J Ophthalmol 1996;80:1073–1076.
   Google Scholar
• Frueh BR, Musch DC. Treatment of facial spasm with botulinum toxin. An interim report. Ophthalmology 1986;93:917–923.
   Google Scholar
• BigIan A, May A, Bowers R. Management of facial spasm with clostridium botulinum toxin, type A (Oculinum). Arch Otolaryngol Head Neck Surg 1988;114:1407–1412.
   Google Scholar
• Patel BCK, Anderson RL. Diagnosis and management of essential blepharospasm. Ophthalmic Pract 1993;11:293–303.
   Google Scholar
• Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997;104:865–868.
   Google Scholar
• Siatkowski RM, Tyutyunikov A, BigIan AW. Serum antibody production to botulinum A toxin. Ophthalmology 1993;100:1861–1866.
   Google Scholar
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743–1746.
   PubMed Web of Science ®Google Scholar
• Aramideh M, Ongerboer de Visser BW, Brans JVVM, Koelman JHTM, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatr 1995;59:309–311.
   PubMed Web of Science ®Google Scholar
• Kristan RW, Stasior OG. Treatment of blepharospasm with high dose brow injection of botulinum toxin. Ophthalmic Plast Reconstr Surg 1987;3:25–27.
   Google Scholar
• Borodic GE, Cozzolino D, Ferrante R, Wiegner AW, Young RR. Innervation zone of orbicularis oculi muscle and implications for botulinum-A toxin therapy. Ophthalmic Plast Reconstr Surg 1991;7:54–60.
   PubMed Web of Science ®Google Scholar
• Taylor JD, Kraft SP, Kazdan MS, et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991;26:133–138.
   PubMed Web of Science ®Google Scholar
• Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol 1994;22:255–260.
   PubMedGoogle Scholar
• Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasm: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51–65.
   Google Scholar
• Gordon G. Observation upon the movement of the eyelids. Br J Ophthalmol 1951;35:339–351.
   PubMed Web of Science ®Google Scholar
• Elston JS. A new variant of blepharospasm. J Neurol Neurosurg Psychiatr 1992;55:369–371.
   Google Scholar
• Aramideh M, Ongerboer de Visser BW, Devriese PP, Bour LJ, Speelman JD. Electromyographic features of levator palpebrae superioris and orbicularis oculi muscles in blepharospasm. Brain, 994;, 17:27–38.
   Google Scholar
• Wiegand H, Erdmann G, Wellhoner HH. 125 I-labelled botulinum A neurotoxin pharmacocinetics in cats after neuromuscular injection. Naunyn-Schmiedebergs Arch Pharrnacol 1976;292: 161–165.
   Google Scholar
• Behari M, Raju GB. Electrophysiological studies in patients with blepharospasm before and after botulinum toxin A therapy. J Neurol Sci 1996;135:74–77.
   Google Scholar
• Patrinely JR, Whiting AS, Anderson RU. Local side effects of botulinum toxin injections. Adv Neurol 1988;49;493–499.
   Google Scholar
• Frueh BR, Nelson CC, Kapustjak JF, Mush DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol 1988;106:45–47.
   Google Scholar
• Nguyen LT, McLoon LK, Wirtschafter JD. Doxorubicin chemomyectomy is enhanced when performed two days following bupivacaine injections: the effect coincides with the peak of muscle satellite cell division. Invest Ophthalmol Visual Sci 1998;39:203–206.
   Google Scholar